Merck presents positive phase 3 results for Keytruda regimen in early-stage breast cancer
Merck & Co – known as MSD outside the US and Canada – has shared positive overall survival (OS) results from a late-stage study of its Keytruda (pembrolizumab) regimen in early-stage breast cancer. The phase 3 KEYNOTE-522 trial has been evaluating Keytruda in combination with chemotherapy as a neoadjuvant treatment before surgery,